CRM197 is commonly used as a carrier protein in protein-polysaccharide conjugation, and CRM197 has many advantages over other carrier proteins, i.e. diphtheria toxoid or tetanus toxoid proteins. Our rCRM197 can be mass-produced from genetically modified E. coli at higher yield. It is currently used for the development of Typhoid Conjugate Vaccine (TCV), Meningococcal Conjugate Vaccine (MCV), and Pneumococcal Conjugate Vaccine (PCV) under development.
| Product Name | rCRM197 |
|---|---|
| Product Purpose | For research purpose and at GMP grade for vaccine development |
| Usage | Carrier protein enhancing the immunogenicity |
| Price | $200/mg |
| Patent |
1) Method for Production of rCRM197 by recombinant E.coil (Patent No.:10-2048456) 2) Expression Method of CRM197 Protein (Patent No.:10-2142255) |
| Research Paper |
1) Production of Carrier Protein rCRM197 Using Recombinant E.coli (https://www.e-ksbbj.or.kr/journal/view.html?uid=145&vmd=Full) 2) An open-label, comparative, single dose, clinical Phase I study to assess the safety and immunogenicity of typhoid conjugate vaccine(Vi-CRM197)in healthy Filipino adults (https://www.sciencedirect.com/science/article/abs/pii/S0264410X21004059?via%3Dihub) 3) Generation of a human monoclonal antibody to cross-reactive material 197 (CRM197) and development of a sandwich ELISA for CRM197 conjugate vaccines (https://www.jmb.or.kr/journal/view.html?doi=10.4014/jmb.1810.10009) |
